LPTX Leap Tx: Enterprise Value-to-Revenue Multiple

Public company logo of Leap Therapeutics Inc (LPTX)

The development of antibodies for the gastrointestinal tract is currently in the R&D stage, which is blocking operational leverage for Leap Therapeutics, Inc. (LPTX). The company's EV/Sales valuation on this GURU.Markets chart reflects this trend, where determines the latest valuation metric. The LPTX business is entirely non-cyclical and resilient to macro shocks, while ownership of unique rights to niche drugs guarantees strong pricing power.

Company Value to Revenue: Leap Tx (LPTX) for 07/04/2022 - 11/20/2026

Leap Tx - analytical breakdowns and key metrics (LPTX)

- share price and consensus valuation forecast:
- money and cash flow information:
Initial company analysis:Leap Therapeutics Inc LPTX
Product sample of Leap Therapeutics Inc

To minimize investment risks, it is necessary to assess the business's actual margin of safety by excluding the impact of debt load on capitalization. By analyzing the EV/Sales history, an investor can see the ratio of the company's total enterprise value to revenue, which helps determine the fairness of the market price relative to the revenues of Leap Therapeutics, Inc. (LPTX) amid effective liquidity management and management's focus on developing its oncology portfolio.

Competitor analysis for Leap Therapeutics, Inc.

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|werewolftx.com (HOWL) - Enterprise Value-to-Revenue Multiple|Immix Biopharma Inc. - EV/Sales Multiple|ALXO - EV/Sales Multiple|CUE: EV/Sales Multiple|Company Value to Revenue Ratio PDSB|Enterprise Value-to-Revenue Ratio Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple LIMN|EV/Sales Multiple Lava Tx (LVTX)|EV/Sales Multiple NXTC (NextCure Corporation)|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP